natgillin/translations-raw huggingface dataset:
Should vaccination with live vaccines be indicated after initiation of Rilonacept Regeneron treatment, the recommendation is to wait for at least 6 weeks after the last Rilonacept Regeneron injection and before the next one (see section 4.4). 
Če je po uvedbi zdravljenja z zdravilom Rilonacept Regeneron indicirano cepljenje z živimi cepivi, priporočamo, da počakate vsaj 6 tednov po zadnji injekciji zdravila Rilonacept Regeneron in 6 tednov pred naslednjo (glejte poglavje 4.4).
• The starting dose is 4.4 milligrams per kilogram of body weight, up to 320 milligrams (mg), given as one or two injections. 
• Začetni odmerek je 4,4 miligrama na kilogram telesne mase, do 320 miligramov (mg), v obliki ene ali dveh injekcij.
Of the 19 patients, 7 tested positive at the last assessment (Week 18 or 24 of the open-label extension period), and 5 patients tested positive for neutralising antibodies on at least one occasion. 
Sedem od teh 19 bolnikov je bilo pozitivnih ob zadnjem testiranju (18. ali 24. teden odprtega podaljšanega obdobja), pri 5 bolnikih pa je bil test za ugotavljanje nevtralizirajočih protiteles pozitiven vsaj enkrat.
The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the medicinal product is on the market. 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, predložen v modulu 1.8.1 dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.
After preparing the Rilonacept Regeneron solution, it is best if used right away because it does not contain a preservative. 
Po pripravi raztopine zdravila Rilonacept Regeneron je najbolje, če jo uporabite takoj, ker ne vsebuje konservansa.
For these reasons, comparison of the incidence of antibodies to rilonacept with the incidence of antibodies to other products may be misleading. 
Zaradi teh razlogov lahko primerjava incidence protiteles proti rilonaceptu z incidenco protiteles proti drugim zdravilom zavaja.
Endpoint Period (Weeks 4 to 6) 
Obdobje končnega stanja (tedni 4 do 6)
If you develop signs of an allergic (hypersensitivity) reaction during treatment with Rilonacept Regeneron (such as chest tightness, wheezing, trouble breathing, severe dizziness or lightheadedness, swelling of lips, or rash during or after the injection) then stop taking Rilonacept Regeneron and tell your doctor right away. 
Če se med zdravljenjem z zdravilom Rilonacept Regeneron pri vas razvijejo znaki alergijske (preobčutljivostne) reakcije (kot so stiskanje v prsnem košu, sopenje, težave z dihanjem, huda omotica ali omedlevica, otekanje ustnic ali izpuščaj med injiciranjem ali po njem), takoj prekinite uporabo zdravila Rilonacept Regeneron in povejte zdravniku.
T1/2 terminal (day) 
Končni razpolovni čas (T1/2) (dni)
Patients who experience vertigo during Rilonacept Regeneron treatment should wait for this to resolve completely before driving or operating machines. 
Bolniki, ki imajo med zdravljenjem z zdravilom Rilonacept Regeneron vrtoglavico, morajo počakati, da ta povsem izzveni, preden začnejo voziti ali upravljati stroje.
The MAH shall complete, within the stated timeframe, the following measures: 
Imetnik dovoljenja za promet z zdravilom mora v spodaj navedenem časovnem okviru izvesti naslednje ukrepe:
The risk for severe hypersensitivity reactions, which is not uncommon for injectable proteins, cannot be excluded (see section 4.3). 
Nevarnosti resnih preobčutljivostnih reakcij, ki pri beljakovinah, ki se injicirajo, niso redke, ne moremo izključiti (glejte poglavje 4.3).
The fact that a limited number of paediatric patients were included in the clinical studies combined with the lack of data on the effect of long term IL-1ß suppression is a concern in view of the orphan nature of the condition. 
Dejstvo, da je bilo vključenih v klinične študije omejeno število pediatričnih bolnikov, skupaj s pomanjkanjem podatkov o učinku dolgoročne supresije IL-1ß, je spričo dejstva, da ima zdravilo Rilonacept Regeneron za otroke naravo zdravila sirote, razlog za pozornost.
No pharmacokinetic data are available in patients with hepatic impairment. 
Pri bolnikih z okvarami jeter ni na voljo nobenih farmakokinetičnih podatkov.
Hold the syringe and needle in your hand ready for injecting. 
Držite brizgo in iglo, pripravljeno na injiciranje, v roki.
This medicine has been given ‘conditional approval'. 
Zdravilo je pridobilo tako imenovano »pogojno dovoljenje za promet«.
• Check the expiration date (month and year) on the Rilonacept Regeneron carton and vial. 
• Preverite rok uporabnosti (mesec in leto) na škatli in viali zdravila Rilonacept Regeneron.
Changes in your blood cholesterol levels or in your blood counts may also occur. 
Lahko nastanejo tudi spremembe koncentracije holesterola v krvi ali vaše krvne slike.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. 
Za navodila o rekonstituciji zdravila pred uporabo glejte poglavje 6.6.
Ask your pharmacist for these supplies. 
Za te potrebščine se obrnite na farmacevta.
Based on limited data obtained from the clinical study, steady-state trough concentrations were similar between male and female patients. 
Na podlagi omejenih podatkov, dobljenih iz klinične študije, so bile minimalne koncentracije v stanju ravnovesja pri bolnicah in bolnikih podobne.
Hypersensitivity to rilonacept or to any of the excipients. 
Preobčutljivost za rilonacept ali katerokoli pomožno snov.
Patients were then given the option to enroll in a 24-week, open-label treatment extension phase during which all patients were treated with rilonacept 160 mg weekly. 
Nato so bolniki imeli možnost, da se vključijo v 24-tedensko fazo podaljšanja odprtega zdravljenja, med katero so vsi bolniki prejemali rilonacept v odmerku 160 mg na teden.
Throw away the vial in the puncture-resistant container even if there is some medicine left in the vial. 
Zavrzite vialo v vsebnik za ostre odpadke, tudi če je v viali še nekaj zdravila.
One patient in an open-label study of CAPS died after developing sinusitis and bacterial (Streptococcus pneumoniae) meningitis. 
En bolnik v odprti študiji CAPS je umrl, potem ko sta se pri njem razvila sinuzitis in bakterijski meningitis (Streptococcus pneumoniae).
• Medicines called Tumour Necrosis Factor (TNF) inhibitors (such as etanercept, adalimumab, or infliximab) predominantly used in rheumatoid and autoimmune disease. 
• zdravila, imenovana zaviralci faktorja tumorske nekroze (TNF) (kot so etanercept, adalimumab ali infliksimab), ki se večinoma uporabljajo za zdravljenje revmatoidne in avtoimunske bolezni;
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP). 
Imetnik dovoljenja za promet z zdravilom bo izvedel farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance sprejetem v RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
Ask your doctor, nurse or pharmacist for advice before taking any medicine. 
Posvetujte se z zdravnikom, medicinsko sestro ali s farmacevtom, preden vzamete katero koli zdravilo.
However, treatment with immunosuppressants, including Rilonacept Regeneron, may result in an increase in the risk of malignancies. 
Vendar pa lahko zdravljenje z imunosupresivi, vključno z zdravilom Rilonacept Regeneron, zveča tveganje malignih bolezni.
Intravenous administration of Rilonacept Regeneron at doses of up to 2000 mg monthly in another patient population for up to six months was generally well-tolerated. 
Intravensko dajanje zdravila Rilonacept Regeneron v odmerkih do 2.000 mg na mesec do šest mesecev so bolniki v neki drugi populaciji na splošno dobro prenašali.
Please read the section “INSTRUCTIONS FOR USE OF RILONACEPT REGENERON POWDER FOR SOLUTION FOR INJECTION” at the end of this leaflet. 
Prosimo vas, da preberete poglavje »NAVODILA ZA UPORABO ZDRAVILA RILONACEPT REGENERON PRAŠEK ZA RAZTOPINO ZA INJICIRANJE« na koncu tega navodila.
• Tell your doctor about any skin reactions including redness, swelling, or hardening of the skin. 
• Obvestite zdravnika o morebitnih kožnih reakcijah, vključno z rdečino, oteklino ali zatrdlino kože.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2 to 8°C. 
Če se zdravilo ne uporabi takoj, je za čas shranjevanja do uporabe, ki normalno ne sme presegati 24 ur pri temperaturi 2 C do 8 C, in pogoje pred uporabo odgovoren uporabnik.
• Skin, eye, or ear infection 
• okužbe kože, oči ali ušes;
Due to the small patient population, an ADR reported in 2 or more patients is classified as “common.” 
Ker je skupina bolnikov majhna, je neželen učinek, o katerem so poročali pri 2 ali več bolnikih, uvrščen med “pogoste”.
• If you touch a needle or the needle touches any surface, throw away the entire syringe into your puncture-resistant container and start over with a new syringe. 
• Če se dotaknete igle ali pa se z iglo dotaknete katere koli druge površine, celotno injekcijsko brizgo zavrzite v vsebnik, odporen na vbode, in postopek ponovno začnite z novo injekcijsko brizgo.
Rilonacept Regeneron blocks the activity of substances including interleukin-1 beta (IL-1 beta). 
Zdravilo Rilonacept Regeneron blokira aktivnost na primer interlevkina-1 beta (IL-1 beta).
See also section 3, “How to inject Rilonacept Regeneron.” 
Glejte tudi poglavje 3 »Kako injicirati zdravilo Rilonacept Regeneron«.
• Bronchitis 
• bronhitis;
• After that, the recommended dose is 1 injection of 2 ml injected once weekly. 
• Po tem je priporočeni odmerek 1 injekcija po 2 ml, injicirana enkrat na teden.
This may lead to symptoms such as fever, headache, fatigue, skin rash, or painful joints and muscles. 
To lahko povzroči simptome, na primer zvišano telesno temperaturo, glavobol, utrujenost, kožni izpuščaj ali bolečine v sklepih in mišicah.
Rilonacept also binds the endogenous IL-1 receptor antagonist (IL-1ra) but with a lower affinity than IL-1β or IL-1α. 
Rilonacept veže tudi endogeni antagonist receptorja IL-1 (IL-1ra), vendar z manjšo afiniteto kot IL-1β ali IL-1α.
Prior to initiation of Rilonacept Regeneron therapy, adult and paediatric patients should receive all recommended vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine. 
Pred uvedbo zdravljenja z zdravilom Rilonacept Regeneron naj odrasli bolniki in otroci prejmejo vsa priporočena cepiva, pač glede na primer, vključno s pnevmokoknim cepivom in inaktiviranim cepivom proti gripi.
Nineteen of 55 patients (35%) who had received Rilonacept Regeneron for at least 6 weeks tested positive for treatment-emergent binding antibodies on at least one occasion. 
Devetnajst od 55 bolnikov (35 %), ki so vsaj 6 tednov prejemali zdravilo Rilonacept Regeneron, je bilo vsaj enkrat pozitivnih na testu za ugotavljanje prisotnosti med zdravljenjem nastalih vezavnih protiteles.
All cases in the clinical trials had a confirmed mutation in the NLRP3 gene. 
Vsi bolniki v kliničnih preskušanjih so imeli potrjeno mutacijo gena NLRP3.
Some symptoms associated with CAPS or with Rilonacept Regeneron treatment, such as a spinning sensation (known as vertigo), may affect your ability to drive or use machines. 
Nekateri simptomi, povezani s CAPS ali z zdravljenjem z zdravilom Rilonacept Regeneron, na primer občutek vrtenja (vrtoglavica ali vertigo) lahko poslabšajo sposobnost vožnje ali upravljanja s stroji.
After the needle is completely in the skin, let go of the skin that you are pinching. 
Ko je igla do konca v koži, spustite kožno gubo, ki ste jo držali.
In a prenatal and postnatal reproductive toxicology study in which mice were dosed subcutaneously, with a murine analogue of rilonacept at doses of 20, 100 or 200 mg/kg three times per week (the highest dose is approximately 6-fold higher than the 160 mg maintenance dose based on body surface area), there were no treatment-related effects. 
V študiji prenatalne in postnatalne reproduktivne toksikologije, v kateri so miši subkutano prejemale mišji analog rilonacepta v odmerkih 20, 100 ali 200 mg/kg trikrat na teden (največji odmerek je približno šestkrat večji od vzdrževalnega odmerka 160 mg na podlagi telesne površine), niso ugotovili nobenih učinkov, povezanih s prejemanjem zdravila.
Rilonacept Regeneron belongs to a group of medicines called interleukin inhibitors. 
Zdravilo Rilonacept Regeneron pripada skupini zdravil, ki se imenujejo zaviralci interlevkinov.
The adult loading dose should be administered as two 2 ml subcutaneous injections (320 mg of rilonacept in total) given on the same day at different sites. 
Polnitveni odmerek za odrasle je treba dati v obliki dveh 2-mililitrskih subkutanih injekcij (skupaj 320 mg rilonacepta) istega dne na različnih mestih.
A significantly higher proportion of patients in the rilonacept group compared to the placebo group experienced improvement from baseline in the composite score by at least 30% (96% vs. 29% of patients), by at least 50% (87% vs. 8%) and by at least 75% (70% vs. 0%) (p<0.0001). 
Signifikantno večjemu deležu bolnikov v skupini z rilonaceptom kot v skupini s placebom se je sestavljeni rezultat izboljšal od izhodišča za vsaj 30 % (96 % proti 29 % bolnikov), za vsaj 50 % (87 % proti 8 %) in za vsaj 75 % (70 % proti 0 %) (p<0,0001).
The first injection of Rilonacept Regeneron should be given under the supervision of a trained healthcare professional. 
Prvo injekcijo zdravila Rilonacept Regeneron je treba dati pod nadzorstvom usposobljenega zdravstvenega delavca.
Further PK steady state exposure data (AUC, Cmax, Cmin during steady state) especially for paediatric subjects is required. 
Potrebni so dodatni PK podatki o izpostavljenosti v stanju dinamičnega ravnovesja (AUC, Cmax, Cmin v stanju dinamičnega ravnovesja), še posebno za otroke.
In a study in patients with polymyalgia rheumatica, one patient developed bronchitis and sinusitis, which resulted in hospitalization. 
V študiji bolnikov z revmatično polimialgijo sta se pri enem bolniku razvila bronhitis in sinuzitis, zaradi katerih je bil bolnik hospitaliziran.
In a study in patients with adult Still's disease, one patient developed an infection in his elbow with Mycobacterium intracellulare after an intraarticular glucocorticoid injection and subsequent local exposure to a suspected source of mycobacteria. 
V študiji na bolnikih s Stillovo boleznijo odraslih se je pri enem bolniku po intraartikularni injekciji glukokortikoidov in poznejši lokalni izpostavljenosti sumljivemu viru mikobakterij v komolcu razvila okužba z Mycobacterium intracellulare.
Immediately after Part A patients entered Part B which consisted of a 9-week, patient-blind period during which all patients received rilonacept 160 mg weekly, followed by a 9-week, double-blind, randomised withdrawal period in which patients were randomly assigned to either remain on rilonacept 160 mg weekly or to receive placebo. 
Takoj po delu A so bolniki vstopili v del B, ki ga je sestavljalo 9-tedensko, za bolnike slepo obdobje, med katerim so vsi bolniki prejemali rilonacept v odmerku 160 mg na teden, ki mu je sledilo 9-tedensko dvojno slepo, randomizirano obdobje odtegnitve, v katerem so bili bolniki naključno izbrani, da ostanejo na rilonaceptu v odmerku 160 mg na teden ali da prejemajo placebo.
The efficacy was not evaluated in patients without a confirmed NLRP3/CIAS1 gene mutation. 
Učinkovitosti niso ugotavljali pri bolnikih brez potrjene mutacije gena NLRP3/CIAS1.
• Serious infections. 
• Resne okužbe.
Rilonacept also led to a significant decrease in serum amyloid A (SAA) versus baseline to levels within the normal range. 
Rilonacept je privedel tudi do tudi signifikantno znižanja plazemskega amiloid A (SAA) glede na izhodiščno vrednost na ravni v normalnih mejah.
Push the plunger down and inject all the air into the vial (see Figure 10). 
Potisnite bat navzdol in injicirajte ves zrak v vialo (glejte sliko 10).
The resulting 80 mg/ml solution is sufficient to allow a withdrawable volume of up to 2 ml for subcutaneous administration. 
Nastale raztopine z 80 mg/ml je dovolj, da lahko iz nje povlečete volumen do 2 ml za subkutano aplikacijo.
After proper training in the correct injection technique, patients may self-inject Rilonacept Regeneron if their physician determines that it is appropriate and with medical follow-up as necessary. 
Potem ko bolnike ustrezno izobrazijo o pravilni tehniki injiciranja, si lahko zdravilo Rilonacept Regeneron injicirajo sami, če njihov zdravnik ugotovi, da je to primerno in da je na voljo medicinska podpora, če je potrebno.
Upon initiation of Rilonacept Regeneron, in patients being treated with these types of medicinal products, therapeutic monitoring of the effect or plasma levels should be performed and the individual dose of the medicinal product may need to be adjusted as needed. 
Po uvedbi zdravila Rilonacept Regeneron je treba pri bolnikih, ki se zdravijo s temi vrstami zdravil, terapevtsko spremljati učinek ali plazemske koncentracije in po potrebi prilagoditi individualni odmerek zdravila.
Part A was a 6-week, randomised, double-blind, placebo-controlled period to evaluate rilonacept at a dose of 160 mg weekly after an initial loading dose of 320 mg. 
Del A je bilo 6-tedensko randomizirano, dvojno slepo, s placebom kontrolirano obdobje za oceno rilonacepta v odmerku 160 mg na teden po začetnem polnitvenem odmerku 320 mg.
In clinical studies, CAPS patients who have uncontrolled over-production of IL-1β show a rapid response to therapy with rilonacept, i.e. laboratory parameters such as C-reactive protein (CRP) and serum amyloid A (SAA) levels, leukocytosis, and high platelet count rapidly returned to normal. 
V kliničnih študijah se bolniki s CAPS, ki imajo nenadzorovano hiperprodukcijo IL-1βhitro odzovejo na zdravljenje z rilonaceptom, t.j., laboratorijski parameteri, na primer koncentracije C-reaktivnega proteina (CRP) in serumskega amiloida A (SAA), levkocitoza in zvišana koncentracija trombocitov, se hitro vrnejo na normalne vrednosti.
Pull the needle out of the skin, and hold a piece of sterile gauze over the injection site for several seconds. 
Povlecite iglo iz kože in nekaj sekund držite kos sterilne gaze na mestu injiciranja.
In placebo-controlled studies across a variety of patient populations encompassing 336 patients treated with rilonacept and 165 treated with placebo, the incidence of infections was 6.8% and 3% (0.44 per patient-exposure year and 0.19 per patient-exposure year), respectively, for rilonacept and placebo. 
V študijah, kontroliranih s placebom, pri različnih skupinah bolnikov, ki so zajele 336 bolnikov, zdravljenih z rilonaceptom, in 165 bolnikov, ki so prejemali placebo, je bila incidenca okužb pri rilonaceptu 6,8 %, pri placebu pa 3 % (0,44 na leto bolnikove izpostavljenosti oziroma 0,19 na leto bolnikove izpostavljenosti).
Week 24 Mean KSS 
Srednji KSS v 24. tednu
Age group (range) 
Starostna skupina (razpon)
In mice, a murine analogue of rilonacept had no effect on fertility. 
Pri miših mišji analog rilonacepta ni vplival na plodnost.
Hold the vial with the solution on a firm surface and wipe the top of the vial with a new alcohol wipe. 
Držite vialo z raztopino na čvrsti površini in obrišite vrh viale z novim alkoholnim zložencem.
From a microbiological safety point of view, the product should be used as soon as possible but within 3 hours of reconstitution, because it does not contain a preservative. 
S stališča mikrobiološke varnosti je treba zdravilo uporabiti takoj, najpozneje pa 3 ure po rekonstituciji, ker ne vsebuje konzervansa.
An increased incidence of serious infections has been associated with administration of another IL-1 inhibitor, in combination with a TNF inhibitor. 
Zvečano incidenco resnih okužb povezujejo z dajanjem drugega zaviralca IL-1, v kombinaciji z zaviralcem TNF.
The subsequent doses are administered as a 2 ml (160 mg of rilonacept) subcutaneous injection once a week. 
Poznejše odmerke dajemo v obliki 2-mililitrske (160 mg rilonacepta) subkutane injekcije enkrat na teden.
It is recommended that neutrophil counts be assessed prior to initiating treatment, after 1 to 2 months, and periodically thereafter while receiving Rilonacept Regeneron. 
Priporočljivo je določiti koncentracijo nevtrofilcev pred uvedbo zdravljenja, po 1 do 2 mesecih in nato v rednih presledkih med prejemanjem zdravila Rilonacept Regeneron.
Neutropenia (absolute neutrophil count [ANC] < 1.5 x 109/l) has been observed commonly with another medicinal product that inhibits IL-1 used in a patient population (rheumatoid arthritis) other than CAPS. 
Nevtropenijo (absolutna koncentracija nevtrofilcev [ANC] < 1,5 x 109/l) so pogosto opazili pri drugih zdravilih, ki zavirajo IL-1 in se uporabljajo pri populaciji bolnikov z drugimi boleznimi (revmatoidni artritis), ne s CAPS.
• The starting dose is 2 injections of 2 millilitres (ml) solution each, given on the same day at 2 different areas of the body. 
• Začetni odmerek sta 2 injekciji po 2 mililitra (ml) raztopine, ki vam ju dajo istega dne na 2 različnih mestih na telesu;
If an area is tender or feels hardened, choose another site for injection until the tenderness or “hardening” goes away. 
Če je predel občutljiv ali je na otip zatrdel, izberite za injekcijo drugo mesto, dokler občutljivost ali zatrdlina ne izgine.
Then slowly and gently, push in the plunger so that all of the air is pushed through the needle. 
Potem pa počasi in previdno potisnite bat tako, da zrak potisnete skozi iglo.
LDPE vials containing 5 ml water for injections Each pack contains: 
Viala z vehiklom viale iz LPDE, ki vsebujejo po 5 ml vode za injekcije Eno pakiranje vsebuje:
For convenience, the corresponding dose volume for weekly injection in paediatric patients is presented in Table 1 below. 
Zaradi prikladnosti so v spodnji preglednici 1 navedeni ustrezni volumni tedenskih injekcij pri pediatričnih bolnikih.
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
C. DRUGI POGOJI IN ZAHTEVE V ZVEZI Z DOVOLJENJEM ZA PROMET Z ZDRAVILOM
In Part B, randomised withdrawal, the incidence of infections were similar in the Rilonacept Regeneron (0%) and the placebo patients (4%). 
V delu B, randomizirana odtegnitev, je bila incidenca okužb pri bolnikih z zdravilom Rilonacept Regeneron (0 %) in s placebom (4 %) podobna.
For the full list of excipients, see section 6.1. 
Za celotni seznam pomožnih snovi glejte poglavje 6.1.
The MAH shall submit an updated risk management plan (RMP) that adequately describes the additional pharmacovigilance activity of performing an embryo-foetal developmental toxicity study in cynomolgus monkeys to further investigate the 
Imetnik dovoljenja za promet z zdravilom bo predložil posodobljen načrt za obvladovanje tveganja (RMP), ki zadostno opiše dodatno farmakovigilančno dejavnost pri izvajanju študije toksičnosti za razvoj zarodka/plodu na makakih za nadaljnje preučevanje morebitnega tveganja za okvare pri plodu.
Turn the syringe so that the needle is facing straight up. 
Obrnite brizgo, tako da igla gleda naravnost navzgor.
If you use more Rilonacept Regeneron than you should If you accidentally inject more Rilonacept Regeneron than the recommended dose, you should contact your doctor right away. 
Če ste uporabili večji odmerek zdravila Rilonacept Regeneron, kot bi smeli Če ste pomotoma injicirali več zdravila Rilonacept Regeneron, kot je priporočeni odmerek, se takoj obrnite na svojega zdravnika.
Dose volume (ml) 
Volumen odmerka (ml)
The ISRs included erythema, swelling, pruritus, and bruising. 
ISR so vključevale eritem, oteklino, pruritus in modrice.
• Allergic reaction 
• alergijska reakcija;
If you do touch the rubber stopper, clean it with a fresh alcohol wipe. 
Če se dotaknete gumijastega zamaška, ga očistite z neuporabljenim alkoholnim robčkom.